Delving into the Latest Updates on Aztreonam lysine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AI, AZLI, Aztreonam lysine (USAN)

+ [5]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesCongenital DisordersDigestive System Disorders+ [2]

Active Indication

Cystic FibrosisInfectious Lung DisorderNon-cystic fibrosis bronchiectasis+ [1]

Inactive Indication

Burkholderia InfectionsGram-Negative Bacterial InfectionsPseudomonas aeruginosa infection+ [1]

Originator Organization

Gilead Sciences, Inc.

Active Organization

Gilead Sciences Ireland UC

Oregon Health & Science University

Gilead Sciences, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

EU (21 Sep 2009),

Cystic FibrosisInfectious Lung Disorder

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H31N7O10S2

InChIKeyKPPBAEVZLDHCOK-JHBYREIPSA-N

CAS Registry827611-49-4

View All Structures (2)

Aims:This study aims to evaluate the efficacy and safety of PARP inhibitor therapy in advanced ovarian cancer and identify the optimal treatment for the survival of patients.Background:The diversity of PARP inhibitors makes clinicians confused about the optimal strategy and the most effective BRCAm mutation-based regimen for the survival of patients with advanced ovarian cancer.Objectives:The objective of this study is to compare the effects of various PARP inhibitors alone or in combination with other agents in advanced ovarian cancer.Methods:PubMed, Embase, Cochrane Library, and Web of Science were searched for relevant studies on PARP inhibitors for ovarian cancer. Bayesian network meta-analysis was performed using Stata 15.0 and R 4.0.4. The primary outcome was the overall PFS, and the secondary outcomes included OS, AE3, DISAE, and TFST.Results:Fifteen studies involving 5,788 participants were included. The Bayesian network metaanalysis results showed that olaparibANDAI was the most beneficial in prolonging overall PFS and non-BRCAm PFS, followed by niraparibANDAI. However, for BRCAm patients, olaparibTR might be the most effective, followed by niraparibANDAI. Olaparib was the most effective for the OS of BRCAm patients. AI, olaparibANDAI, and veliparibTR were more likely to induce grade 3 or higher adverse events. AI and olaparibANDAI were more likely to cause DISAE.Conclusion:PARP inhibitors are beneficial to the survival of patients with advanced ovarian cancer. The olaparibTR is the most effective for BRCAm patients, whereas olaparibANDAI and niraparibANDAI are preferable for non-BRCAm patients.Other:More high-quality studies are desired to investigate the efficacy and safety of PARP inhibitors in patients with other genetic performances.

01 Dec 2024·Journal of Medical Imaging and Radiation Sciences

The future of radiology and radiologists: AI is pivotal but not the only change afoot

Article

Author: Weisberg, Edmund M ; Fishman, Elliot K

Uncertainty regarding the future of radiologists is largely driven by the emergence of artificial intelligence (AI). If AI succeeds, will radiologists continue to monopolize imaging services? As AI accuracy progresses with alacrity, radiology reads will be excellent. Some articles show that AI can make non-radiologists experts. However, eminent figures within AI development have expressed concerns over its possible adverse uses. Bad actors, not bad AI, may account for a future in which AI is not as successful as we might hope and, as some fear, even pernicious. More relevant to current predictions over the course of AI in medicine, and radiology in particular, is how the evolution of AI is often seen in a vacuum. We cannot predict the future with certainty. But as we contemplate the potential impact of AI in radiology, we should remember that radiology does not exist in a vacuum; while AI is changing, so is everything else. The medical system, not to mention the world's population, has been severely impacted by the global COVID-19 pandemic and numerous experts expect future worldwide pandemics. We cannot predict the condition of the healthcare system in two decades but may assume that radiology will likely remain critical in any future medical practice. For now, we should responsibly use all tools at our disposal (including AI) to make ourselves as indispensable as possible. Our best chances of remaining relevant and instrumental to patient care will likely hinge on our ability to lead the changes rather than be passively impacted by them.

01 Nov 2024·BMJ Supportive & Palliative CareQ3 · MEDICINE

Cognitive complaints during breast cancer endocrine therapy: aromatase inhibitors versus tamoxifen

Q3 · MEDICINE

Article

Author: Berrazega, Yosra ; Rachdi, Haifa ; Mejri, Nesrine ; Boussen, Hamouda ; Laabidi, Soumaya ; Abdallah, Ichrak Ben

ObjectivePrevious data hypothesise that women receiving aromatase inhibitors (AIs) exhibit worse cognitive functioning than patients on tamoxifen (TAM) since their oestrogen levels are lower. We aimed to compare cognitive complaints in both groups.MethodsFrom September 2020 to January 2021, we conducted a cross-sectional study on patients with stage I–III breast cancer undergoing adjuvant endocrine therapy for at least 6 months. Cognitive complaints were assessed using the Functional Assessment of Cancer Therapy–Cognitive V.3 questionnaire with higher scores indicating better outcomes.ResultsWe included 108 female patients, 60 on AI and 48 on TAM. Mean age at diagnosis was 52 (44 in the TAM group vs 58 in the AI group, p<0.001). Assessment of ‘perceived cognitive impairment-20 subscale’ did not identify a significant difference between the two groups (mean score: patients on AI=63/80 vs patients on TAM=58/80, p=0.198). Patients on TAM scored significantly worse than patients on AI (p<0.001) on the concentration complaints, while for the verbal domain, memory, multitasking, speed and functional interference, no significant difference between the two groups was observed. The difference in concentration complaints was maintained after adjustment to age, educational level, physical activity, prior exposure to chemotherapy, and living alone or with others. Finally, a favourable impact of regular physical activity on concentration scores was observed in both groups (p<0.001).ConclusionDespite age difference, patients on AI did not demonstrate worse complaints than patients on TAM. Patients on TAM exhibited significantly increased concentration complaints. Oncologists should carefully screen their patients for mental fog and educate them on the importance of regular exercise.

100 Deals associated with Aztreonam lysine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06558	-	J01DF01	DB00355

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cystic Fibrosis	EU	Gilead Sciences Ireland UC	21 Sep 2009
Cystic Fibrosis	NO	Gilead Sciences Ireland UC	21 Sep 2009
Cystic Fibrosis	IS	Gilead Sciences Ireland UC	21 Sep 2009
Cystic Fibrosis	LI	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	EU	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	LI	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	IS	Gilead Sciences Ireland UC	21 Sep 2009
Infectious Lung Disorder	NO	Gilead Sciences Ireland UC	21 Sep 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burkholderia Infections	Phase 3	CA	Gilead Sciences, Inc.	01 Feb 2010
Burkholderia Infections	Phase 3	US	Gilead Sciences, Inc.	01 Feb 2010
Infectious Lung Disorder	Phase 3	CA	Gilead Sciences, Inc.	01 May 2008
Infectious Lung Disorder	Phase 3	AU	Gilead Sciences, Inc.	01 May 2008
Pseudomonas Infections	Phase 3	AU	Gilead Sciences, Inc.	01 May 2008
Pseudomonas Infections	Phase 3	US	Gilead Sciences, Inc.	01 May 2008
Pseudomonas Infections	Phase 3	CA	Gilead Sciences, Inc.	01 May 2008
Infectious Lung Disorder	Discovery	US	Gilead Sciences, Inc.	01 May 2008
Cystic Fibrosis	Discovery	US	Gilead Sciences, Inc.	01 Feb 2005
Cystic Fibrosis	Discovery	US	Gilead Sciences, Inc.	01 Feb 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03219164 (ALPINE2 \| ALPINE 2, CTgov)	Phase 3	Pseudomonas aeruginosa infection \| Cystic Fibrosis	149	Placebo+AZLI (AZLI 14 Days + Placebo 14 Days)	kyhspdmvaw(alwlwdflys) = omdbwkoftl jfjhbsuvsq (jjyhnpplkd, kgpipiogts - mvufnjbgvn) View more	-	16 May 2022
				aztreonam (AZLI 28 Days)	kyhspdmvaw(alwlwdflys) = rifopoxrkp jfjhbsuvsq (jjyhnpplkd, psocmyblgg - wefnoxmonw) View more
CSCO2021	Not Applicable	Soft Tissue Sarcoma	28	安罗替尼+AI	pnvdtmbsaj(mmfazbitxh) = 67.86% pbdczdmbmh (kwfuppoefu ) View more	-	25 Sep 2021
NCT01641822 (AZLI CAT, CTgov)	Phase 3	Pseudomonas Infections \| Cystic Fibrosis \| Infectious Lung Disorder	107	Tobramycin inhalation solution+AZLI (AZLI)	abatxvizrp(glokaxfvej) = tvskwvjlyy jrsiuchrug (mqgbnmfwup, hmibbctytn - ushaeekrgm) View more	-	09 May 2016
				Placebo to match AZLI+Tobramycin inhalation solution (Placebo)	abatxvizrp(glokaxfvej) = pzgtvhrvcq jrsiuchrug (mqgbnmfwup, rbkudvuiio - rvfxyjdldu) View more
NCT01404234 (PALS, CTgov)	Phase 3	Pseudomonas Infections \| Cystic Fibrosis	61	AZLI	mxjtahrbwi(vizjapnkif) = vcndqzseeu dhuxnchstv (wscigrfzys, dexxxrgide - snhyxsmpdn) View more	-	01 May 2014
NCT01314716 (AIR-BX2, CTgov)	Phase 3	Non-cystic fibrosis bronchiectasis \| Gram-Negative Bacterial Infections	274	AZLI (AZLI-AZLI)	dgrndmifpj(anqbmkqbtq) = zchbhwxawl nopuknnkcq (iptkvydraf, dkumsjoluw - ruzubkwiaw) View more	-	16 Apr 2014
				Placebo+AZLI (Placebo-AZLI)	dgrndmifpj(anqbmkqbtq) = rrfycoegol nopuknnkcq (iptkvydraf, gwwyczjiva - pghhfiwzfw) View more
NCT01313624 (AIR-BX1, CTgov)	Phase 3	Non-cystic fibrosis bronchiectasis \| Gram-Negative Bacterial Infections	266	AZLI (AZLI-AZLI)	yijqlcqmny(kxvuvguaay) = cptrjjkgcw ityajcbfmb (fmdickmjsy, wbsiyubxfm - ulshmeiwai) View more	-	16 Apr 2014
				Placebo+AZLI (Placebo-AZLI)	yijqlcqmny(kxvuvguaay) = unopfurtlk ityajcbfmb (fmdickmjsy, dolekivgrz - ekjctnmvuy) View more
NCT00805025 (CTgov)	Phase 2	Bronchiectasis	89	AZLI	opensngmia(nlgrfzirsi) = vjaknluhws slbvwamfmc (smenozjjee, zkkrxkjikm - whwunxfiaj) View more	-	20 Mar 2014
NCT01059565 (CTgov)	Phase 3	Cystic Fibrosis \| Burkholderia Infections	102	AZLI (AZLI)	uivihldtht(siivufudzj) = yujdyjchfx fselrefari (gztxtiwzep, kmfdrpjkii - uqwebgqlwb) View more	-	11 Mar 2014
				Placebo (Placebo)	uivihldtht(siivufudzj) = qzaqqytccj fselrefari (gztxtiwzep, ecrvwzjrxm - oxlohuqmlk) View more
NCT00112359 (AIR-CF1, CTgov)	Phase 3	Cystic Fibrosis	166	Placebo (Placebo TID)	xcdzhobejx(czwtfdaqjs) = msusurgjod duiwnihscv (rcyqrcwwcb, rhwewihcxu - mlgwuzgcyc) View more	-	21 Apr 2011
				AZLI (75 mg AZLI TID)	xcdzhobejx(czwtfdaqjs) = nybgqhgdvs duiwnihscv (rcyqrcwwcb, fgfavhtwkx - irkyoeluaz) View more
NCT00104520 (AIR-CF2, CTgov)	Phase 3	Cystic Fibrosis	211	Placebo (Placebo (Pooled BID/TID))	dlxyczkhvx(xszxpkikav) = mivcquomds lhyaacnjej (rwgfhuhitl, giuienfbyy - qtugicsiwl) View more	-	11 Mar 2011
				AZLI (AZLI (Pooled BID/TID))	dlxyczkhvx(xszxpkikav) = kbwgqpkhpq lhyaacnjej (rwgfhuhitl, cgdxzmadwu - twmzlwfvjv) View more